机器学习改善亚洲MASLD患者显著纤维化预测:GO-ASIA研究
优化随机森林模型在整体、测试和验证集中排除显著纤维化的NPV/F1均优于FIB-4,可减少不必要转诊并避免漏诊。
要点
- 机器学习模型检测显著纤维化的判别力比FIB-4提高7%-12%。
- 优化随机森林整体集NPV 0.947、F1 0.754,优于FIB-4的0.744/0.499。
- 随机森林较FIB-4可多识别10倍显著纤维化患者,减少28%不必要转诊。
核心结论
- 在活检证实的亚洲NAFLD/MASLD患者中,基于临床、人体测量和简单血液指标的机器学习模型排除显著纤维化的性能优于FIB-4。
主要发现
- 患者中位年龄47岁,54.6%为男性,73.7%有代谢综合征,32.9%有组织学显著纤维化。
- 显著纤维化患者较无显著纤维化者年龄、转氨酶、空腹血糖、代谢综合征、未控制糖尿病和NAFLD活动度评分更高(p < 0.001)。
- 机器学习模型检测显著纤维化的判别力比FIB-4提高7%-12%。
- 优化随机森林在整体集、测试集和验证集的NPV/F1分别为0.947/0.754、0.798/0.588、0.852/0.559;FIB-4分别为0.744/0.499、0.722/0.456、0.806/0.507。
- 与FIB-4相比,随机森林可多识别10倍显著纤维化患者,减少28%不必要转诊,避免78%漏诊转诊;年龄、AST、ALT、空腹血糖和血小板计数是决定显著纤维化的主要特征。
关键数值与推荐
- 模型选择标准为NPV和F1-score。
- 序贯使用SAFE < 140及SAFE > 140时FIB-4 < 1.2排除显著纤维化的NPV在整体集、测试集和验证集分别为0.757、0.724和0.827。
临床怎么用
- 在亚洲NAFLD/MASLD患者中,可考虑用基于临床和简单血液指标的机器学习模型替代FIB-4来排除显著纤维化,以减少不必要转诊并避免漏诊。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The precise estimation of cases with significant fibrosis (SF) is an unmet goal in non-alcoholic fatty liver disease (NAFLD/MASLD). AIMS: We evaluated the performance of machine learning (ML) and non-patented scores for ruling out SF among NAFLD/MASLD patients. METHODS: Twenty-one ML models were trained (N = 1153), tested (N = 283), and validated (N = 220) on clinical and biochemical parameters of histologically-proven NAFLD/MASLD patients (N = 1656) collected across 14 centres in 8 Asian countries. Their performance for detecting histological-SF (≥F2fibrosis) were evaluated with APRI, FIB4, NFS, BARD, and SAFE (NPV/F1-score as model-selection criteria). RESULTS: Patients aged 47 years (median), 54.6% males, 73.7% with metabolic syndrome, and 32.9% with histological-SF were included in the study. Patients with SFvs.no-SF had higher age, aminotransferases, fasting plasma glucose, metabolic syndrome, uncontrolled diabetes, and NAFLD activity score (p < 0.001, each). ML models showed 7%-12% better discrimination than FIB-4 to detect SF. Optimised random forest (RF) yielded best NPV/F1 in overall set (0.947/0.754), test set (0.798/0.588) and validation set (0.852/0.559), as compared to FIB4 in overall set (0.744/0.499), test set (0.722/0.456), and validation set (0.806/0.507). Compared to FIB-4, RF could pick 10 times more patients with SF, reduce unnecessary referrals by 28%, and prevent missed referrals by 78%. Age, AST, ALT fasting plasma glucose, and platelet count were top features determining the SF. Sequential use of SAFE < 140 and FIB4 < 1.2 (when SAFE > 140) was next best in ruling out SF (NPV of 0.757, 0.724 and 0.827 in overall, test and validation set). CONCLUSIONS: ML with clinical, anthropometric data and simple blood investigations perform better than FIB-4 for ruling out SF in biopsy-proven Asian NAFLD/MASLD patients.
引用
- Verma N, Duseja A, Mehta M, et al. Machine learning improves the prediction of significant fibrosis in Asian patients with metabolic dysfunction-associated steatotic liver disease - The Gut and Obesity in Asia (GO-ASIA) Study. Aliment Pharmacol Ther. 2024. PMID: 38303507. doi:10.1111/apt.17891
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。